Brief: Sichuan Kelun-Biotech Biopharmaceutical Says Trop2 Adc Sacituzumab Tirumotecan Approved For Marketing For Fourth Indication By China's NMPA
06/02/2026 10:33
Feb 6 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK: TROP2 ADC SACITUZUMAB TIRUMOTECAN APPROVED FOR MARKETING FOR FOURTH INDICATION BY NMPA Further company coverage: 6990.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sichuan Kelun-Biotech Biopharmaceutical
See all newsBrief: Sichuan Kelun-Biotech Biopharmaceutical Subscribes To CZB Structured Deposit VI For RMB500 Mln
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says NMPA Accepts New Indication Application For SAC-TMT
Brief: Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results Of Skb378/Win378 In Asthma, And Initiates Phase 3 Study
China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals
Brief: Sichuan Kelun-Biotech Biopharmaceutical Posts HY Net Income Attributable Of RMB 388 MLN